Literature DB >> 19933935

Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men.

Jyrki K Virtanen1, Jaakko Mursu, Sari Voutilainen, Tomi-Pekka Tuomainen.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia. Regular fish consumption has been shown to reduce the risk of AF in some but not all studies. Long-chain n-3 polyunsaturated fatty acids (PUFAs) from fish have been suggested to account for these beneficial effects. We tested this hypothesis by studying the association between the serum long-chain n-3 PUFAs eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid and risk of AF in men. METHODS AND
RESULTS: A total of 2174 men from the prospective population-based Kuopio Ischemic Heart Disease Risk Factor Study, 42 to 60 years old and free of AF at baseline in 1984 to 1989, were studied. During the average follow-up time of 17.7 years, 240 AF events occurred. In the Cox proportional hazards model, the multivariable-adjusted hazard ratio in the highest (>5.33%) versus the lowest (<3.61%) quartile of eicosapentaenoic acid plus docosapentaenoic acid plus docosahexaenoic acid was 0.65 (95% confidence interval 0.44 to 0.96, P for trend=0.07). Evaluated individually, only serum docosahexaenoic acid was associated with the risk of AF (hazard ratio in the highest versus the lowest quartile 0.62, 95% confidence interval 0.42 to 0.92, P for trend=0.02). Exclusion of subjects (n=233) with myocardial infarction or congestive heart failure either at baseline or that preceded the AF event during follow-up slightly strengthened the associations. Serum intermediate chain-length n-3 PUFA, alpha-linolenic acid, or hair methylmercury concentration were not associated with the risk.
CONCLUSIONS: An increased concentration of long-chain n-3 PUFAs in serum, a marker of fish or fish oil consumption, may protect against AF. Serum docosahexaenoic acid concentration had the greatest impact.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933935     DOI: 10.1161/CIRCULATIONAHA.109.852657

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  59 in total

Review 1.  The evidence for α-linolenic acid and cardiovascular disease benefits: Comparisons with eicosapentaenoic acid and docosahexaenoic acid.

Authors:  Jennifer A Fleming; Penny M Kris-Etherton
Journal:  Adv Nutr       Date:  2014-11-14       Impact factor: 8.701

Review 2.  Diet and risk of atrial fibrillation – epidemiologic and clinical evidence –.

Authors:  Noelle N Gronroos; Alvaro Alonso
Journal:  Circ J       Date:  2010-09-11       Impact factor: 2.993

Review 3.  (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Nutr       Date:  2012-01-25       Impact factor: 4.798

4.  Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study.

Authors:  Jason H Y Wu; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Frank M Sacks; Eric B Rimm; Susan R Heckbert; David S Siscovick; Dariush Mozaffarian
Journal:  Circulation       Date:  2012-01-26       Impact factor: 29.690

5.  Serum long-chain omega-3 polyunsaturated fatty acids and risk of orthostatic hypotension.

Authors:  Asenath N Nyantika; Tomi-Pekka Tuomainen; Jussi Kauhanen; Sari Voutilainen; Jyrki K Virtanen
Journal:  Hypertens Res       Date:  2016-02-25       Impact factor: 3.872

Review 6.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 7.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

Review 8.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

9.  Alpha-linolenic acid: is it essential to cardiovascular health?

Authors:  Johanna M Geleijnse; Janette de Goede; Ingeborg A Brouwer
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

Review 10.  Omega-3 PUFAs and atrial fibrillation: have we made up our mind yet?

Authors:  Federico Guerra; Matilda Shkoza; Lorena Scappini; Laura Roberti; Alessandro Capucci
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.